. Author manuscript; available in PMC: 2014 Nov 1.

Published in final edited form as: Cancer. 2013 Aug 6;119(21):3870–3878. doi: 10.1002/cncr.28298

Table 1.

Patterns of lenalidomide initiation, use of other MDS therapies, duration and dose, overall and for del5qMDS and other lower risk MDS.

				MDS Risk Group

		Overall		del5qMDS		Other Risk	Lower-

		N	%	N	%	N	%

Cohort N, % of total		23,855	100.0	480	2.0	6355	26.6
Any LEN use, % of total % of cohort receiving		753	100.0	149	19.8	182	24.2
LEN^†		3.2		31.0		2.9
LEN use by MDS diagnosis period
2006-first half^†		143	3.1	19	32.2	21	3.2
2006-second half^†		144	3.6	26	35.1	32	3.2
2007-first half^†		165	3.3	30	25.9	46	3.1
2007-second half^†		109	3.2	32	36.0	32	2.8
2008-first half^†		123	3.0	35	37.6	33	2.5
LEN use only post MDS diagnosis†		690	2.9	141	29.9	169	2.7
Time to LEN Initiation from MDS diagnosis (weeks)^*

Median^†		11.5		8		20
Minimum		0		0		0
Maximum		132		89		125
Mean^†		23.7		14.8		27.7
S.e.		1.0		1.5		2.0
Use of ESAs and DNMTi among LEN Users^*
		N	%	N	%	N	%

Any Use	ESA^†	545	79.0	105	74.5	148	87.6
Any Use	DNMTi^†	149	21.6	17	12.1	50	29.6
Prior to LEN initiation	ESA^†	499	72.3	91	64.5	143	84.6
Prior to LEN initiation	DNMTi^†	81	11.7	^**		^**
Concurrent with LEN use	ESA^†	389	56.4	86	61.0	98	58.0
Concurrent with LEN use	DNMTi^†	30	4.3	^**		^**
After LEN discontinuation	ESA	200	29.0	36	25.5	58	34.3
After LEN discontinuation	DNMTi	76	11.0	^**		^**
Duration, adherence of LEN use
# 28 day cycles supplied
Mean (s.e.)	4.1	0.18	5.1	0.47	4.2	0.34
Median	2		3		2
Maximum	29.8		29.8		26
Received > 3 cycles(%)	34.3		44.7		36.7
Average daily dose (mg)^*
< 3.8	30	4.3	^**		^**
3.8 -- 4.9	57	8.3	17	12.1	12	8.5
5.0 -- 7.5	286	41.4	69	48.9	66	46.8
7.6 -- 9.9	43	6.2	11	7.8	13	9.2
10.0 -- 15.0	236	34.2	34	24.1	58	41.1
>15.0	38	5.5	^**			^**

Restricted to Medicare beneficiaries with continuous Part A/B/D coverage who were first dispensed lenalidomide on or after the incident MDS diagnosis in 2006-2008,first episode of lenalidomide

^**

Suppressed due to small sample size.

^†

Differences between del5q and other LR MDS significant at p<0.01

Abbreviations: N: number, LEN: lenalidomide; s.e.: standard error; ESA: erythropoiesis-stimulating agents; GCSF: Granulocyte colony stimulating factors, DNMTi: DNA methyltransferase inhibitors.

Source: 100% Medicare enrollment and claims for beneficiaries with MDS, enrolled in Medicare Part D, 2006-2008)